bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version portfolio  foresite capital strategy portfolio about team news contact portfolio featured companies revolutionizing type  diabetes and obesityintarcias device is a matchsticksized osmotic pump that delivers glp glucagonlike peptide in a manner that avoids the need for regular painful injections while producing efficacy and tolerability resultsprotecting people from food allergensaimmune’s characterized oral desensitization immunotherapy codit™ system combines proprietary product candidates with gradual controlled updosing protocols to obtain meaningful desensitization to food allergens changing the definition of sequencingwith the gemcode platform x genomics researchers can now find structural variants haplotypes and other valuable long range information while leveraging existing sequencing workflowsaddressing glaucoma with tripleaction eyedropsaerie is developing firstinclass oncedaily eye drops with the ability to reduce intraocular pressure iop in patients with openangle glaucoma and ocular hypertensionreversing tumors associated with immunosuppressionarcus is pursuing smallmolecule and proteinbased therapeutics to block active immunosuppression pathways and selectively stimulate the tumorkilling activity of effector immune cellsdeveloping therapeutic antibodies to maximize efficacyalders ald is a novel monoclonal antibody targeting calcitonin generelated peptide cgrp in phase  trials for the prevention of migraine headaches full portfolio  any biopharmaceuticalbiotechnologydrugdevice combinations and medical devicesgenomics tools and data sciencehealthcare services and data sciencepharmaceuticals team  foresite capital strategy portfolio about team news contact our team investment team specifically constructed to identify evaluate and fund what we believe are the best opportunities in healthcare each member of our team brings a diverse and complementary set of skills experience and networks to help accelerate company growth foresite’s principals draw on their track record of developing and launching revolutionary healthcare products and leading financings with successful outcomes alvin tam trading operations manager brett zbar managing director collin yangwong investment analyst dennis d ryan cfo  managing director dorothy margolskee managing director james klinect quantitative analyst jim tananbaum ceo  managing director luke bagaason investment analyst matthew buten managing director michael rome senior analyst molly he venture partner noah dennis investment analyst phil kallos director of engineering rhonda kaufman director richard lau senior investment analyst spencer knight data scientist stephen c peterson senior investment analyst tony wiemelt associate director strategy  foresite capital strategy portfolio about team news contact strategy our focus we are a trusted financial partner with a structure that allows us to partner with portfolio company management to develop complete financing solutions in both private and public markets ​​​​​​ we invest in emerging leaders across all areas of healthcare including therapeutics medical devices diagnostics and services our focus is on the development and commercialization of transformative products that address what we believe are the most critical unmet healthcare needs how were different we are a financial partner at all stages – venture and postventure private and public – partnering at the point where we believe we can make the biggest impact we function as a team participating together in primary diligence and sharing collective ownership of our investment and portfolio management decisions our collaborative team culture allows us to bring an array of unique perspectives and evaluate situations efficiently and effectively we provide a depth and breadth of insights and best practices from our experience with hundreds of companies to each of our ventures we have powerful highquality networks and deep experience across areas of healthcare including marketing sales business development research and development regulatory policy and communications the healthcare sector is experiencing unprecedented innovation driven by understanding vast amounts of biologic and genetic information a change we believe is leading to some of the most impactful medical solutions in decades innovation is increasingly focused on improving care and reducing costs our passion is to use our capital and networks to help build transformative healthcare companies and build a portfolio of companies that significantly impact the quality and effectiveness of the us healthcare system jim tananbaum ceo  managing director foresite capital strategy portfolio about team news contact helping build healthcare leaders we provide capital and support to help companies with transformative products and services become healthcare leaders scaling innovation through close collaboration with visionary entrepreneurs and a relentless focus on innovation and building value we aim to dramatically enhance patient care portfolio developing therapeutic antibodies to maximize efficacyprotecting people from food allergensaddressing glaucoma with tripleaction eyedropschanging the definition of sequencingreversing tumors associated with immunosuppressionrevolutionizing type  diabetes and obesity see full portfolio accelerating growth since our inception in  our strategy has been to offer complete capital solutions to help build categorydefining companies across therapeutics devices diagnostics and healthcare services b assets under management  funds closed  diverse team members news apr  prepare for the digital health revolution apr  foresite capital ceo jim tananbaum featured on the forbes midas list for the third year in a row apr  foresite capital announces ceo jim tananbaum named to forbes’ midas list  apr  adaptimmune raises m for pipeline work kalobios chief says biotech is on track for chagas drug filing see all news portfolio  foresite capital strategy portfolio about team news contact portfolio featured companies revolutionizing type  diabetes and obesityintarcias device is a matchsticksized osmotic pump that delivers glp glucagonlike peptide in a manner that avoids the need for regular painful injections while producing efficacy and tolerability resultsprotecting people from food allergensaimmune’s characterized oral desensitization immunotherapy codit™ system combines proprietary product candidates with gradual controlled updosing protocols to obtain meaningful desensitization to food allergens changing the definition of sequencingwith the gemcode platform x genomics researchers can now find structural variants haplotypes and other valuable long range information while leveraging existing sequencing workflowsaddressing glaucoma with tripleaction eyedropsaerie is developing firstinclass oncedaily eye drops with the ability to reduce intraocular pressure iop in patients with openangle glaucoma and ocular hypertensionreversing tumors associated with immunosuppressionarcus is pursuing smallmolecule and proteinbased therapeutics to block active immunosuppression pathways and selectively stimulate the tumorkilling activity of effector immune cellsdeveloping therapeutic antibodies to maximize efficacyalders ald is a novel monoclonal antibody targeting calcitonin generelated peptide cgrp in phase  trials for the prevention of migraine headaches full portfolio  any biopharmaceuticalbiotechnologydrugdevice combinations and medical devicesgenomics tools and data sciencehealthcare services and data sciencepharmaceuticals about us  foresite capital strategy portfolio about team news contact about foresite what we do we provide growth capital to emerging healthcare leaders with disruptive products and services with the goal of transforming patient care foresite capital typically invests small amounts in its initial investment in a portfolio company  million can invest in private and public securities and can invest significant capital over time   million into portfolio company securities foresite capital’s goal is to help portfolio companies grow from proofofconcept to revenue growth and profitability foresite capital provides strategic insight creativity drive and networks of highvalue professionals in addition to capital to its portfolio companies   we built foresite with a deep multidisciplinary and highly experienced team in order to optimize sourcing evaluation and growth acceleration with more than b in assets under management as of june  we apply insight creativity and drive to earn the trust of our portfolio companies how we work our investment team possesses more than  years of collective experience in the healthcare and investment industries we believe this broad and deep experience has produced a bestinclass network of contacts to help our portfolio companies accelerate growth internally our team functions collaboratively with each member of the team participating at all stages of the investment process foresite capital’s due diligence and decisionmaking process is structured to understand and help portfolio companies mitigate key technical regulatory execution and competitive risks contact us  foresite capital strategy portfolio about team news contact contact us email us your name your email your number your comment sf  montgomery street suite  san francisco ca  tel    ny  avenue of the americas rd floor new york ny  tel    jim tananbaum  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt jim tananbaum ceo  managing director highlights founded foresite capital in  cofounded geltex which was acquired for  billion by sanofigenzyme cofounded theravance inc total market cap of b which subsequently changed its name to innoviva inc nasdaq inva and with its spinoff theravance biopharma inc nasdaq tbph the companies have a combined market capitalization of  billion earned bs and bsee from yale university in applied math and computer science and ms from mit md and mba from harvard university member of yale’s university council and the advisory committee of the yale school of engineering  applied science    midas list jim is the founder of foresite capital and an industry leader with  years of healthcare entrepreneurial and investing experience jim focuses on strategic operational and financial opportunities to build franchise healthcare businesses he has been the chief architect of foresite capital’s investment organization structure and investment strategy and has played a significant role in numerous foresite capital portfolio companies prior to founding foresite capital jim cofounded two leading biopharmaceutical companies and two healthcare investment practices while finishing harvard university  medical and business schools and earning an ms from the massachusetts institute of technology mit he founded geltex pharmaceuticals nasdaqgenz which brought two drugs to market for less than  million geltex was acquired in  for  billion when its lead drug renagel renzela had an annual revenue run rate in excess of  million today renzela is estimated to produce close to  billion in annual revenue  years after its launch jim also cofounded and was ceo of theravance inc who share gsk’s respiratory franchise through a joint venture innoviva nasdaq inva and completed a spinoff theravance biopharma inc nasdaq tbph  the two companies have a combined market capitalization of approximately  billion jim’s investment experience includes being a founding partner of prospect venture partners ii and iii and earlier in his career  a partner at sierra ventures where he helped establish its healthcare services investment practice jim has led numerous investments including amira pharmaceuticals acquired by nyse bms amerigroup nasdaq amgp healtheon nasdaqwbmd and jazz pharmaceuticals nasdaq jazz  jim founded foresite capital with the vision of marrying elements of all aspects of his career to create a novel investment platformjim graduated with a bs and bsee from yale university an md from harvard medical school an ms from mit and an mba from harvard business school he has served on the advisory boards and visiting committees to the harvardmit hst program and on yale’s president advisory counsel alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt foresite capital management iii llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors foresite capital management iii llc check out list of companies and businesses related to foresite capital management iii llc find out foresite capital management iii llc address and contact details view other people related to foresite capital management iii llc  coworkers colleagues companions etc address  california street suite  san francisco  ca companies related to foresite capital management iii llc cikcompany namepositioncompany addressaerie pharmaceuticals inc kit creek road suite  research triangle park aimmune therapeutics inc marina boulevard suite  brisbane intellia therapeutics inc erie street suite  cambridge  foresite capital management iii llc on the web persons related to foresite capital management iii llc  aerie pharmaceuticals incnamepositioncityacmp iv llcsan franciscoacmp iv llcsan franciscoacp iv lp owner san franciscoacp iv lpsan franciscomehra anandbridgewatermehra anandbedminstervicente anido jrchief executive officer irvinevicente anido jrchief executive officer bedminsterdavid bondermanfort worthdavid bondermanfort worthlevy brianbedminstereric buatoismenlo parkeric buatoismenlo parkgerald d cagledirector bedminsterkopczynski caseybridgewaterkopczynski caseybedminsterclarus lifesciences ii lp owner cambridgeclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgejanet l conwaybedminsterjames g coulterfort worthjames g coulterfort worthrichard croarkindirector irvineepstein davidresearch triangle parkepstein davidbridgewaterepstein davidbedminstergryska davidbedminstermack davidsan franciscomack davidbridgewatermack davidbedminsterhenner dennisbedminstertoit michael dudirector new yorkgeoffrey m duykdirector geoffrey m duykfort worthgeoffrey m duykfort worthgeoffrey m duykdirector fort worthforesite capital fund ii lpsan franciscoforesite capital fund iii lpsan franciscoforesite capital management ii llc owner san francisconicholas galakatoscambridgeduyk geoffreysan franciscoduyk geoffreybridgewaterduyk geoffreybedminstercagle geraldbedminstermurray a goldbergdirector murray a goldbergdirector bedminsterdavid w gryskadirector south san franciscodavid w gryskadirector bedminsterjames healymenlo parkjames healymenlo parkdennis hennercambridgemazzo jamesbedminsterconway janetresearch triangle parkconway janetbridgewaterconway janetbedminsterdaniel janneysan franciscodaniel janneysan franciscocasey c kopczynskichief scientific officer bedminsterbrian levychief medical officer rochesterbrian levychief medical officer bedminsterrobert liptakcambridgedavid henry macksan franciscojames v mazzodirector bedminsterbenjamin f mcgraw iiidirector irvinebenjamin f mcgraw iiibedminsterjulie mchughdirector chadds fordanand mehradirector menlo parkanand mehra owner menlo parkanand mehradirector menlo parkdelong mitchellbridgewaterthomas a mitropresident and coo irvinethomas a mitropresident and coo bedminstergoldberg murraybedminstergoldberg murraybedminsterguy p nohrasan franciscoguy p nohrasan franciscomichael powellmenlo parkmichael powellmenlo parkrubino richardbedminsterrichard j rubinochief financial officer franklin lakesrichard j rubinochief financial officer bedminsternicholas simoncambridgesofinnova management vii llcmenlo parksofinnova management vii llcmenlo parksofinnova venture partners vii l pmenlo parksofinnova venture partners vii l p owner menlo parkmichael steinmetzcambridgejames b tananbaumsan franciscomitro thomasbedminstervan haarlem thomasbridgewatervan haarlem thomasbedminstertpg group holdings sbs advisors inc fort worthtpg group holdings sbs advisors inc owner fort worthanido vicentebedminsterkurt wheelercambridgepersons related to foresite capital management iii llc  aimmune therapeutics incnamepositioncitydaniel c md adelmanchief medical officer south san franciscosusan e barrowcliffegeneral manager europe brisbanegregory behardirector cambridgeeric bjerkholtchief financial officer palo altowalser bryansan mateowarren l desouzachief financial officer brisbanestephen george dillypresident and ceo alamedarobert myles elfontchief medical officer brisbanepatrick g enrightdirector burlingamekathryn e falbergdirector rockvilleforesite capital fund ii lpsan franciscoforesite capital fund iii lpsan franciscoforesite capital management ii llc owner san franciscomark t iwickidirector marlboroughtananbaum jamessan franciscoanthony yun joonkyoosan mateojeffrey h knappchief operating officer fremontlongitude capital partners ii llc owner menlo parklongitude venture partners ii lpmenlo parkmark mcdadedirector nestle health science us holdings incnorwalksa nestlevevey switzerlandnimco us incnorwalkenright patrickmenlo parkhoward v raffbrisbanemary m rozenmansee remarks brisbanestacey denenberg seltzerdirector brisbanedouglas t sheehysee remarks redwood cityseltzer staceynew yorkdilly jr stephensan mateobakker juliet tammenomsmenlo parkjames b tananbaumsan franciscocolunga victorsan mateopersons related to foresite capital management iii llc  intellia therapeutics incnamepositioncityatlas venture associates ix lp owner cambridgeatlas venture associates ix llccambridgeatlas venture fund ix lp owner cambridgebaker bros advisors gp llcnew yorkbaker bros advisors llc new yorkfelix bakerjulian bakerthomas m barnessvp rd extellia cambridgegraeme bellevp chief financial officer palo altonessan berminghampresident  ceo cambridgecaribou biosciences incberkeleycaribou therapeutics holdco llc owner berkeleygordon carlcambridgecaroline dorsadirector whitehouse stationforesite capital fund iii lpsan franciscojean francois formeladirector fullerton management pte ltdsingaporecarl l gordondirector new yorkrachel e haurwitzdirector cambridgenicole heifnersvp accounting cambridgesamuel d isalyformela jeanfrancoiscambridgeleonard johncambridgerivera josecambridgeperry a karsendirector rockvillejohn m leonardevp rd north chicagodavid v morrisseysvp platform  delivery tech cambridgebermingham nessancambridgeag novartisch baselnovartis institutes for biomedical research inc owner cambridgeorbimed advisors llcdirector orbimed capital gp v llcnew yorkorbimed global healthcare gp llcnew yorkhaurwitz rachelcambridgejose e riveraevp general counsel  ops cambridgemoncef slaouidirector cambridgesapna srivastavacedar knollsjames b tananbaumsan franciscotemasek holdings ltd owner singaporetemasek life sciences private ltdsingaporetls beta pte ltdsingaporefrank verwieldirector brisbane aimmune therapeutics nasdaqaimt stock price news  analysis aimmune therapeutics company profile nasdaqaimt company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about aimmune therapeutics nasdaqaimt aimmune therapeutics inc is a clinicalstage biopharmaceutical company developing a therapeutic approach including the development of product candidates for the treatment of peanut and other food allergies the companys therapeutic approach which it refers to as characterized oral desensitization immunotherapy codit is a system designed to desensitize patients to food allergens using characterized biologic products defined treatment protocols and support services the companys lead codit product candidate ar is an investigational biologic for the treatment of patients with peanut allergy the company has initiated peanut allergy oral immunotherapy study of ar for desensitization in children and adults palisade its phase iii registration trial of ar the company is in the process of evaluating additional delivery forms for ar for the maintenance phase industry sector and symbol sector medical industry specialty  advanced pharmaceuticals subindustry na symbol nasdaqaimt cusip na web wwwaimmunecom capitalizationmarket cap  billionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue naprice  sales nabook value  per shareprice  book  profitabilityebidta return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for aimmune therapeutics nasdaqaimt what is aimmune therapeutics stock symbol aimmune therapeutics trades on the nasdaq under the ticker symbol aimt how were aimmune therapeutics earnings last quarter aimmune therapeutics inc nasdaqaimt released its quarterly earnings results on monday may th the company reported  earnings per share eps for the quarter beating the thomson reuters consensus estimate of  by  view aimmune therapeutics earnings history when will aimmune therapeutics make its next earnings announcement aimmune therapeutics is scheduled to release their next quarterly earnings announcement on tuesday august th  view earnings estimates for aimmune therapeutics where is aimmune therapeutics stock going where will aimmune therapeutics stock price be in   analysts have issued month price objectives for aimmune therapeutics shares their forecasts range from  to  on average they anticipate aimmune therapeutics share price to reach  in the next year view analyst ratings for aimmune therapeutics what are analysts saying about aimmune therapeutics stock here are some recent quotes from research analysts about aimmune therapeutics stock  according to zacks investment research aimmune therapeutics inc is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies the companys characterized oral desensitization immunotherapy includes ar a product for the treatment of peanut allergy in children and adults which is in clinical trial stage aimmune therapeutics inc is headquartered in brisbane california    piper jaffray companies analysts commented today aimmune reported q financial results ending the quarter with m in cash we think this cash funds the company through at least ye by this time we should have results from its phase iii palisade program in peanut allergy and we see compelling efficacy as well as safety here as the key valuecreating event for aimt shares around yeearly  by ye we also expect a bla filing submitted for use in kids and teens based on guidance of bla timing and assuming the full year for bla prep filing and review despite the btd status granted to ar were modestly adjusting first us pedsteens sales from  to  resulting in a new pt of  despite this change we continue to recommend aimt in advance of month clinical progress including importantly palisade updosing completion around mid which we see as potentially reducing clinical risk for the program  who are some of aimmune therapeutics key competitors some companies that are related to aimmune therapeutics include supernus pharmaceuticals supn repligen corporation rgen therapeuticsmd txmd therapeuticsmd txmd eagle pharmaceuticals egrx assembly biosciences asmb rockwell medical rmti novan novn checkcap chek cormedix crmd advanced accelerator applications sa aaap dara biosciences dara macrocure ltd mcur and salix pharmaceuticals slxp who are aimmune therapeutics key executives aimmune therapeutics management team includes the folowing people mark d mcdade independent chairman of the boardstephen g dilly md phd president chief executive officer directoreric h bjerkholt chief financial officerjeffrey h knapp chief operating officersusan e barrowcliffe senior vice president general manager of europemary m rozenman senior vice president  strategy and corporate developmentdouglas t sheehy jd general counsel secretarysue barrowcliffe general manager of europedaniel c adelman md chief medical officergreg behar independent director when did aimmune therapeutics ipo aimt raised  million in an initial public offering ipo on thursday august th  the company issued  shares at  per share bofa merrill lynch credit suisse and piper jaffray acted as the underwriters for the ipo who owns aimmune therapeutics stock aimmune therapeutics stock is owned by a number of of retail and institutional investors top institutional investors include emerald advisers inc pa  emerald mutual fund advisers trust  strs ohio  russell investments group ltd  franklin street advisors inc nc  and daiwa sb investments ltd  company insiders that own aimmune therapeutics stock include douglas t sheehy eric bjerkholt foresite capital fund ii lp longitude capital partners ii mary m rozenman stephen george dilly susan e barrowcliffe and warren l desouza view institutional ownership trends for aimmune therapeutics who sold aimmune therapeutics stock who is selling aimmune therapeutics stock aimmune therapeutics stock was sold by a variety of institutional investors in the last quarter including emerald advisers inc pa franklin street advisors inc nc russell investments group ltd and daiwa sb investments ltd company insiders that have sold aimmune therapeutics stock in the last year include douglas t sheehy mary m rozenman stephen george dilly susan e barrowcliffe and warren l desouza view insider buying and selling for aimmune therapeutics who bought aimmune therapeutics stock who is buying aimmune therapeutics stock aimmune therapeutics stock was bought by a variety of institutional investors in the last quarter including strs ohio company insiders that have bought aimmune therapeutics stock in the last two years include eric bjerkholt and longitude capital partners ii view insider buying and selling for aimmune therapeutics how do i buy aimmune therapeutics stock shares of aimmune therapeutics can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is aimmune therapeutics stock price today one share of aimmune therapeutics stock can currently be purchased for approximately  marketbeat community rating for aimmune therapeutics nasdaq aimtcommunity ranking   out of     outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about aimmune therapeutics and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for aimmune therapeutics nasdaqaimt how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for aimmune therapeutics nasdaqaimt show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailspiper jaffray companiesset price targetbuylowwedbushreiterated ratingoutperformmediumjmp securitiesinitiated coverageoutperformnacredit suisse groupreiterated ratingbuynabank of america corporationreiterated ratingbuynadata available from  forward earnings earnings history for aimmune therapeutics nasdaqaimtearnings history by quarter for aimmune therapeutics nasdaq aimtdatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsnaq viewnaq viewnaq viewnaqviewnaqviewnaqviewlistenq viewnadata available from  forward estimates earnings estimates for aimmune therapeutics nasdaqaimt eps consensus estimate  eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q q q q q data provided by zacks investment research dividends dividend history for aimmune therapeutics nasdaqaimtno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for aimmune therapeutics nasdaqaimtinsider ownership percentage institutional ownership percentage insider trades by quarter for aimmune therapeutics nasdaqaimttransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailssusan e barrowcliffeinsidersell  douglas t sheehyinsidersell  mary m rozenmaninsidersell  mary m rozenmaninsidersell  susan e barrowcliffeinsidersell  stephen george dillyinsidersell  eric bjerkholtcfobuy  stephen george dillyinsidersell  warren l desouzacfosell  warren l desouzacfosell  mary m rozenmaninsidersell  mary m rozenmaninsidersell  mary m rozenmaninsidersell  foresite capital fund ii lpmajor shareholdersell  longitude capital partners iimajor shareholderbuy  data available from  forward headlines headline trends for aimmune therapeutics nasdaqaimt latest headlines for aimmune therapeutics nasdaqaimt source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlineaimmune therapeutics inc aimt downgraded by zacks investment research to sellwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc expected to post fy earnings of  per share nasdaqaimtwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc expected to earn fy earnings of  per share nasdaqaimtwwwamericanbankingnewscom  july  at  pmsusan e barrowcliffe sells  shares of aimmune therapeutics inc nasdaqaimt stockwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc nasdaqaimt given outperform rating at wedbushwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc aimt insider sells  in stockwwwamericanbankingnewscom  july  at  pmaimmune banks on food allergies study expected to show positive resultsseekingalphacom  july  at  amaimmune therapeutics inc aimt given average rating of buy by brokerageswwwamericanbankingnewscom  july  at  pminsider selling aimmune therapeutics inc aimt insider sells  shares of stockwwwamericanbankingnewscom  july  at  pm earnings per share expected for aimmune therapeutics inc aimt this quarterwwwamericanbankingnewscom  july  at  amaimmune therapeutics inc aimt downgraded to hold at zacks investment researchwwwamericanbankingnewscom  july  at  pmaveo pharmaceuticals aveo worth a look stock up financeyahoocom  july  at  pmaimmune therapeutics inc nasdaqaimt insider susan e barrowcliffe sells  shareswwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc nasdaqaimt insider sells  in stockwwwamericanbankingnewscom  july  at  pmaimmune therapeutics aimt reports enrollment of st patient in artemis arc european phase  clinical trial of arwwwstreetinsidercom  july  at  pmaimmune therapeutics enrolls first patient in artemis arc european phase  clinical trial of ar for the treatment of peanut allergyfinanceyahoocom  july  at  pmaimmune therapeutics aimt shares march higher can it continuefinanceyahoocom  june  at  pmaimmune therapeutics inc aimt insider sells  in stockwwwamericanbankingnewscom  june  at  pmaimmune therapeutics inc aimt given consensus rating of buy by brokerageswwwamericanbankingnewscom  june  at  amaimmune therapeutics aimt presents european phase  palisade screening data at eaaciwwwstreetinsidercom  june  at  pmdynavax technologies dvax catches eye stock gains financeyahoocom  june  at  pmaimmune therapeutics presents european phase  palisade screening data at  european academy of allergy and clinical immunology eaaci congressfinanceyahoocom  june  at  pmzacks analysts expect aimmune therapeutics inc aimt will announce earnings of  per sharewwwamericanbankingnewscom  june  at  amaimmune therapeutics inc aimt upgraded by zacks investment research to buywwwamericanbankingnewscom  june  at  pmaimmune therapeutics aimt to present data on peanut allergy in europe at eaaciwwwstreetinsidercom  june  at  pmaimmune therapeutics to present data on peanut allergy in europe at the european academy of allergy and clinical immunology eaaci congress financeyahoocom  june  at  pmaimmune therapeutics inc aimt lifted to hold at valuenginewwwamericanbankingnewscom  june  at  pmaimmune therapeutics reports on updosing in its ongoing phase  palisade trial of ar for peanut allergyfinanceyahoocom  june  at  pmaimmune therapeutics inc aimt lowered to hold at zacks investment researchwwwamericanbankingnewscom  june  at  pmclearwater project targets peanut allergiesfinanceyahoocom  june  at  pmaimmune therapeutics to present at the goldman sachs th annual global healthcare conference on thursday june thfinanceyahoocom  june  at  pmaimmune therapeutics cuts ribbon on commercial manufacturing facility to support potential launch of treatment for peanut allergyfinanceyahoocom  june  at  pmaimmune therapeutics inc aimt receives consensus rating of buy from analystswwwamericanbankingnewscom  may  at  amaimmune therapeutics inc aimt stock rating lowered by valuenginewwwamericanbankingnewscom  may  at  pmaimmune therapeutics inc aimt upgraded by zacks investment research to buywwwamericanbankingnewscom  may  at  pmwhy these drug stocks may surgefinanceyahoocom  may  at  americ bjerkholt acquires  shares of aimmune therapeutics inc aimt stockwwwamericanbankingnewscom  may  at  pminsider selling aimmune therapeutics inc aimt insider sells  shares of stockwwwamericanbankingnewscom  may  at  pmbriefaimmune therapeutics enrolls first patient in latestage trial of its peanut allergy drugwwwreuterscom  may  at  pmwedbush comments on aimmune therapeutics incs q  earnings aimtwwwamericanbankingnewscom  may  at  amwedbush equities analysts boost earnings estimates for aimmune therapeutics inc aimtwwwamericanbankingnewscom  may  at  pmaimmune therapeutics aimt announces enrollment of first patient in ramses arc a phase  clinical trial of arwwwstreetinsidercom  may  at  pmaimmune therapeutics enrolls first patient in ramses arc a phase  clinical trial of ar for the treatment of peanut allergyfinanceyahoocom  may  at  pmaimmune therapeutics inc aimt releases earnings resultswwwamericanbankingnewscom  may  at  pmaimmune therapeutics to present at the bank of america merrill lynch healthcare conference on tuesday may financeyahoocom  may  at  amaimmune therapeutics announces first quarter  financial resultsfinanceyahoocom  may  at  pmaimmune therapeutics reports q lossmarketbeatcom  may  at  pmaimmune therapeutics aimt receiving somewhat critical press coverage alphaone reportswwwamericanbankingnewscom  may  at  amaimmune therapeutics inc aimt receives average recommendation of buy from brokerageswwwamericanbankingnewscom  may  at  pmbiotechs cruise on day upswing despite price target cuts for this duofinanceyahoocom  may  at  pm social chart aimmune therapeutics aimt chart for friday july   this page was last updated on  by marketbeatcom staff aimmune therapeutics nasdaqaimt stock price news  analysis aimmune therapeutics company profile nasdaqaimt company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about aimmune therapeutics nasdaqaimt aimmune therapeutics inc is a clinicalstage biopharmaceutical company developing a therapeutic approach including the development of product candidates for the treatment of peanut and other food allergies the companys therapeutic approach which it refers to as characterized oral desensitization immunotherapy codit is a system designed to desensitize patients to food allergens using characterized biologic products defined treatment protocols and support services the companys lead codit product candidate ar is an investigational biologic for the treatment of patients with peanut allergy the company has initiated peanut allergy oral immunotherapy study of ar for desensitization in children and adults palisade its phase iii registration trial of ar the company is in the process of evaluating additional delivery forms for ar for the maintenance phase industry sector and symbol sector medical industry specialty  advanced pharmaceuticals subindustry na symbol nasdaqaimt cusip na web wwwaimmunecom capitalizationmarket cap  billionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue naprice  sales nabook value  per shareprice  book  profitabilityebidta return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for aimmune therapeutics nasdaqaimt what is aimmune therapeutics stock symbol aimmune therapeutics trades on the nasdaq under the ticker symbol aimt how were aimmune therapeutics earnings last quarter aimmune therapeutics inc nasdaqaimt released its earnings results on monday may th the company reported  earnings per share for the quarter beating analysts consensus estimates of  by  view aimmune therapeutics earnings history when will aimmune therapeutics make its next earnings announcement aimmune therapeutics is scheduled to release their next quarterly earnings announcement on tuesday august th  view earnings estimates for aimmune therapeutics where is aimmune therapeutics stock going where will aimmune therapeutics stock price be in   brokers have issued month price targets for aimmune therapeutics shares their forecasts range from  to  on average they expect aimmune therapeutics stock price to reach  in the next year view analyst ratings for aimmune therapeutics what are analysts saying about aimmune therapeutics stock here are some recent quotes from research analysts about aimmune therapeutics stock  according to zacks investment research aimmune therapeutics inc is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies the companys characterized oral desensitization immunotherapy includes ar a product for the treatment of peanut allergy in children and adults which is in clinical trial stage aimmune therapeutics inc is headquartered in brisbane california    piper jaffray companies analysts commented today aimmune reported q financial results ending the quarter with m in cash we think this cash funds the company through at least ye by this time we should have results from its phase iii palisade program in peanut allergy and we see compelling efficacy as well as safety here as the key valuecreating event for aimt shares around yeearly  by ye we also expect a bla filing submitted for use in kids and teens based on guidance of bla timing and assuming the full year for bla prep filing and review despite the btd status granted to ar were modestly adjusting first us pedsteens sales from  to  resulting in a new pt of  despite this change we continue to recommend aimt in advance of month clinical progress including importantly palisade updosing completion around mid which we see as potentially reducing clinical risk for the program  who are some of aimmune therapeutics key competitors some companies that are related to aimmune therapeutics include supernus pharmaceuticals supn repligen corporation rgen therapeuticsmd txmd therapeuticsmd txmd eagle pharmaceuticals egrx assembly biosciences asmb rockwell medical rmti novan novn checkcap chek cormedix crmd advanced accelerator applications sa aaap dara biosciences dara macrocure ltd mcur and salix pharmaceuticals slxp who are aimmune therapeutics key executives aimmune therapeutics management team includes the folowing people mark d mcdade independent chairman of the boardstephen g dilly md phd president chief executive officer directoreric h bjerkholt chief financial officerjeffrey h knapp chief operating officersusan e barrowcliffe senior vice president general manager of europemary m rozenman senior vice president  strategy and corporate developmentdouglas t sheehy jd general counsel secretarysue barrowcliffe general manager of europedaniel c adelman md chief medical officergreg behar independent director when did aimmune therapeutics ipo aimt raised  million in an initial public offering on thursday august th  the company issued  shares at  per share bofa merrill lynch credit suisse and piper jaffray acted as the underwriters for the ipo who owns aimmune therapeutics stock aimmune therapeutics stock is owned by a number of of retail and institutional investors top institutional investors include emerald advisers inc pa  emerald mutual fund advisers trust  strs ohio  russell investments group ltd  franklin street advisors inc nc  and daiwa sb investments ltd  company insiders that own aimmune therapeutics stock include douglas t sheehy eric bjerkholt foresite capital fund ii lp longitude capital partners ii mary m rozenman stephen george dilly susan e barrowcliffe and warren l desouza view institutional ownership trends for aimmune therapeutics who sold aimmune therapeutics stock who is selling aimmune therapeutics stock aimmune therapeutics stock was sold by a variety of institutional investors in the last quarter including emerald advisers inc pa franklin street advisors inc nc russell investments group ltd and daiwa sb investments ltd company insiders that have sold aimmune therapeutics stock in the last year include douglas t sheehy mary m rozenman stephen george dilly susan e barrowcliffe and warren l desouza view insider buying and selling for aimmune therapeutics who bought aimmune therapeutics stock who is buying aimmune therapeutics stock aimmune therapeutics stock was acquired by a variety of institutional investors in the last quarter including strs ohio company insiders that have bought aimmune therapeutics stock in the last two years include eric bjerkholt and longitude capital partners ii view insider buying and selling for aimmune therapeutics how do i buy aimmune therapeutics stock shares of aimmune therapeutics can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is aimmune therapeutics stock price today one share of aimmune therapeutics stock can currently be purchased for approximately  marketbeat community rating for aimmune therapeutics nasdaq aimtcommunity ranking   out of     outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about aimmune therapeutics and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for aimmune therapeutics nasdaqaimt how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for aimmune therapeutics nasdaqaimt show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailspiper jaffray companiesset price targetbuylowwedbushreiterated ratingoutperformmediumjmp securitiesinitiated coverageoutperformnacredit suisse groupreiterated ratingbuynabank of america corporationreiterated ratingbuynadata available from  forward earnings earnings history for aimmune therapeutics nasdaqaimtearnings history by quarter for aimmune therapeutics nasdaq aimtdatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsnaq viewnaq viewnaq viewnaqviewnaqviewnaqviewlistenq viewnadata available from  forward estimates earnings estimates for aimmune therapeutics nasdaqaimt eps consensus estimate  eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q q q q q data provided by zacks investment research dividends dividend history for aimmune therapeutics nasdaqaimtno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for aimmune therapeutics nasdaqaimtinsider ownership percentage institutional ownership percentage insider trades by quarter for aimmune therapeutics nasdaqaimttransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailssusan e barrowcliffeinsidersell  douglas t sheehyinsidersell  mary m rozenmaninsidersell  mary m rozenmaninsidersell  susan e barrowcliffeinsidersell  stephen george dillyinsidersell  eric bjerkholtcfobuy  stephen george dillyinsidersell  warren l desouzacfosell  warren l desouzacfosell  mary m rozenmaninsidersell  mary m rozenmaninsidersell  mary m rozenmaninsidersell  foresite capital fund ii lpmajor shareholdersell  longitude capital partners iimajor shareholderbuy  data available from  forward headlines headline trends for aimmune therapeutics nasdaqaimt latest headlines for aimmune therapeutics nasdaqaimt source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlineaimmune therapeutics inc aimt downgraded by zacks investment research to sellwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc expected to post fy earnings of  per share nasdaqaimtwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc expected to earn fy earnings of  per share nasdaqaimtwwwamericanbankingnewscom  july  at  pmsusan e barrowcliffe sells  shares of aimmune therapeutics inc nasdaqaimt stockwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc nasdaqaimt given outperform rating at wedbushwwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc aimt insider sells  in stockwwwamericanbankingnewscom  july  at  pmaimmune banks on food allergies study expected to show positive resultsseekingalphacom  july  at  amaimmune therapeutics inc aimt given average rating of buy by brokerageswwwamericanbankingnewscom  july  at  pminsider selling aimmune therapeutics inc aimt insider sells  shares of stockwwwamericanbankingnewscom  july  at  pm earnings per share expected for aimmune therapeutics inc aimt this quarterwwwamericanbankingnewscom  july  at  amaimmune therapeutics inc aimt downgraded to hold at zacks investment researchwwwamericanbankingnewscom  july  at  pmaveo pharmaceuticals aveo worth a look stock up financeyahoocom  july  at  pmaimmune therapeutics inc nasdaqaimt insider susan e barrowcliffe sells  shareswwwamericanbankingnewscom  july  at  pmaimmune therapeutics inc nasdaqaimt insider sells  in stockwwwamericanbankingnewscom  july  at  pmaimmune therapeutics aimt reports enrollment of st patient in artemis arc european phase  clinical trial of arwwwstreetinsidercom  july  at  pmaimmune therapeutics enrolls first patient in artemis arc european phase  clinical trial of ar for the treatment of peanut allergyfinanceyahoocom  july  at  pmaimmune therapeutics aimt shares march higher can it continuefinanceyahoocom  june  at  pmaimmune therapeutics inc aimt insider sells  in stockwwwamericanbankingnewscom  june  at  pmaimmune therapeutics inc aimt given consensus rating of buy by brokerageswwwamericanbankingnewscom  june  at  amaimmune therapeutics aimt presents european phase  palisade screening data at eaaciwwwstreetinsidercom  june  at  pmdynavax technologies dvax catches eye stock gains financeyahoocom  june  at  pmaimmune therapeutics presents european phase  palisade screening data at  european academy of allergy and clinical immunology eaaci congressfinanceyahoocom  june  at  pmzacks analysts expect aimmune therapeutics inc aimt will announce earnings of  per sharewwwamericanbankingnewscom  june  at  amaimmune therapeutics inc aimt upgraded by zacks investment research to buywwwamericanbankingnewscom  june  at  pmaimmune therapeutics aimt to present data on peanut allergy in europe at eaaciwwwstreetinsidercom  june  at  pmaimmune therapeutics to present data on peanut allergy in europe at the european academy of allergy and clinical immunology eaaci congress financeyahoocom  june  at  pmaimmune therapeutics inc aimt lifted to hold at valuenginewwwamericanbankingnewscom  june  at  pmaimmune therapeutics reports on updosing in its ongoing phase  palisade trial of ar for peanut allergyfinanceyahoocom  june  at  pmaimmune therapeutics inc aimt lowered to hold at zacks investment researchwwwamericanbankingnewscom  june  at  pmclearwater project targets peanut allergiesfinanceyahoocom  june  at  pmaimmune therapeutics to present at the goldman sachs th annual global healthcare conference on thursday june thfinanceyahoocom  june  at  pmaimmune therapeutics cuts ribbon on commercial manufacturing facility to support potential launch of treatment for peanut allergyfinanceyahoocom  june  at  pmaimmune therapeutics inc aimt receives consensus rating of buy from analystswwwamericanbankingnewscom  may  at  amaimmune therapeutics inc aimt stock rating lowered by valuenginewwwamericanbankingnewscom  may  at  pmaimmune therapeutics inc aimt upgraded by zacks investment research to buywwwamericanbankingnewscom  may  at  pmwhy these drug stocks may surgefinanceyahoocom  may  at  americ bjerkholt acquires  shares of aimmune therapeutics inc aimt stockwwwamericanbankingnewscom  may  at  pminsider selling aimmune therapeutics inc aimt insider sells  shares of stockwwwamericanbankingnewscom  may  at  pmbriefaimmune therapeutics enrolls first patient in latestage trial of its peanut allergy drugwwwreuterscom  may  at  pmwedbush comments on aimmune therapeutics incs q  earnings aimtwwwamericanbankingnewscom  may  at  amwedbush equities analysts boost earnings estimates for aimmune therapeutics inc aimtwwwamericanbankingnewscom  may  at  pmaimmune therapeutics aimt announces enrollment of first patient in ramses arc a phase  clinical trial of arwwwstreetinsidercom  may  at  pmaimmune therapeutics enrolls first patient in ramses arc a phase  clinical trial of ar for the treatment of peanut allergyfinanceyahoocom  may  at  pmaimmune therapeutics inc aimt releases earnings resultswwwamericanbankingnewscom  may  at  pmaimmune therapeutics to present at the bank of america merrill lynch healthcare conference on tuesday may financeyahoocom  may  at  amaimmune therapeutics announces first quarter  financial resultsfinanceyahoocom  may  at  pmaimmune therapeutics reports q lossmarketbeatcom  may  at  pmaimmune therapeutics aimt receiving somewhat critical press coverage alphaone reportswwwamericanbankingnewscom  may  at  amaimmune therapeutics inc aimt receives average recommendation of buy from brokerageswwwamericanbankingnewscom  may  at  pmbiotechs cruise on day upswing despite price target cuts for this duofinanceyahoocom  may  at  pm social chart aimmune therapeutics aimt chart for friday july   this page was last updated on  by marketbeatcom staff foresite capital  financial services firm san francisco california  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagesforesite capital foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees share foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description foresite capital is a ria based in sf ca with b in aum information type ria head quarters sf ca  of employees  total assets  website location  montgomery st sf ca   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on march   b total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  there are no advisors from this firm to display at this time affiliated investment advisors and broker dealers name type total assets foresite capital ia management llc   foresite capital iiia management llc   foresite capital management i llc   foresite capital management ii llc   foresite capital management iii llc   foresite capital va management llc   foresite capital vb management llc   foresite capital vc management llc   foresite capital vd management llc   leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership james bruce tananbaum manager trustee july   to  dana shonfeld tananbaum trustee july   to  dennis drew ryan chief financial officer managing director and chief compliance officer january  less than  source sec fees types of compensation arrangements percentage of assets performancebased fees company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations foresite capital  financial services firm san francisco california  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagesforesite capital foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees share foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description foresite capital is a ria based in sf ca with b in aum information type ria head quarters sf ca  of employees  total assets  website location  montgomery st sf ca   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on march   b total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  there are no advisors from this firm to display at this time affiliated investment advisors and broker dealers name type total assets foresite capital ia management llc   foresite capital iiia management llc   foresite capital management i llc   foresite capital management ii llc   foresite capital management iii llc   foresite capital va management llc   foresite capital vb management llc   foresite capital vc management llc   foresite capital vd management llc   leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership james bruce tananbaum manager trustee july   to  dana shonfeld tananbaum trustee july   to  dennis drew ryan chief financial officer managing director and chief compliance officer january  less than  source sec fees types of compensation arrangements percentage of assets performancebased fees company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations f portfolio foresite capital management iii llc stock ideas hedge fund trade spotlight high conviction ipo stocks biotech stocks that hedge funds are buying top undervalued stock picks  stocks that matter most to hedge funds stocks validate your stock consensus stock picks realtime insights hedge funds hedge fund portfolios hedge fund managers find your hedge fund match hm pro pro stock screener institutional portfolios institutional investors sign insubscribe nowweeks free trial hedgemindcom   institutional portfolios   foresite capital management iii llc    find institutional investor institutional investor browse institutional investors time period activityallnewincreasedunchangeddecreasedsold out security typeallstockoptions put callfixed income top percentileuse this filter to see holdings within a selected percentile portfoliofor example click  to show only holdings in the top  percentile sectorsuse the pull down list to add one or more sectors to the space below and click apply to filter out the holdings that belong to your selected sectorsapply clear select a sector basic industriescapital goodsconsumer durablesconsumer nondurablesconsumer servicesenergyfinancehealth caremiscellaneouspublic utilitiestechnologytransportationnaunidentified stock stylestock style shows hedge fund managers main investment focus in value or growth it is determined based on analysis of portfolio holdings that are part of about  us stocksresetstylemarket caplargevaluemidblendsmallgrowth foresite capital management iii llc time period total holdings total value x activities newincreasedunchangeddecreasedsold out top  stock holdingstotal  aerialdrakaoaimtwvenbspepzmblcmbpmcnstgderm  hover over a symbol below for details  sec ffilingdetail sortportfolio weight growth or valueposition valuechange ratesectorazgraphaericomaldrcomakaocomaimtcomwveshsepzmcomblcmcombpmccomnstgcomdermcommntacomptgxcomloxocomacrscomasndsponsored adrirtccomntracomfgencomntlacomjncecomzfgncomorexcom newboldcomimmucomxlrncomeditcomaktxsponsored adrgbtcom   hedgemindcom llc all rights reserved site mapdisclaimertermsprivacycontact us brightscope  advisor pages  find a financial advisor or advisory firm getsearchtypedisplaynamesearchtype advisor funds firms k plans general search advisors advisory firms financial qa k plans funds search home    brightscope advisor pages    find a financial advisory firm advisor search firm search advisors by city find a financial advisory firm search firm name active firms only city state alabama alaska american samoa arizona arkansas california colorado connecticut delaware district of columbia florida georgia guam hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota northern marinara islands ohio oklahoma oregon pennsylvania puerto rico rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming firm service areas financial planning estate planning comprehensive financial planning retirement planning college planning charitable planning other financial planning tax planning insurance life insurance health insurance longterm care insurance annuities property  casualty insurance business insurance other insurance pension consulting k b  defined benefit other pension consulting portfolio management individuals andor small businesses investment companies businesses or institutional clients other portfolio management accounting  tax tax advice other tax legal legal planning legal advice other legal other publication of periodicals or newsletters security ratings or pricing services market timing services selection of other advisors educational seminarsworkshops see all service areas find filters financialplanningfindfirm compensation arrangements no preference fixed fees  hourly charges  performancebased fees  none  fee only  assets under mgmt no preference   k  m  m  m  m  m  m  b  b  avg account balance no preference   k  k  k  k  m  m  m  m  m  financial advisory firm search results  results merrill lynch pierce fenner  smith incorporated ny ny  advisors  aum  b wells fargo advisors llc st louis mo  advisors  aum  b jp morgan securities llc manhattan ny  advisors  aum  b morgan stanley smith barney llc harrison ny  advisors  aum  b lpl financial llc boston ma  advisors  aum  b edward d jones  co lp des peres mo  advisors  aum  b ameriprise financial services inc minneapolis mn  advisors  aum  b ubs financial services inc weehawken nj  advisors  aum  b northwestern mutual investment servicesllc milwaukee wi  advisors charles schwab  co inc south beach ca  advisors mml investors services llc pine point ma  advisors  aum  b goldman sachs  co ny ny  advisors  aum  b strategic advisers inc boston ma  advisors  aum  b citigroup global markets inc new york ny  advisors  aum  b raymond james  associates inc st petersburg fl  advisors  aum  b      company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations foresite capital management iii llc top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active foresite capital management iii llc • san francisco ca how do i update this listing foresite capital management iii is based out of san francisco their last reported f filing for q  included  in managed f securities and a top  holdings concentration of  foresite capital management iiis largest holding is aerie pharmaceuticals with shares held of  whalewisdom has at least  f filings in our database for foresite capital management iii summary f holdings ind managers dg insider form  download f summary to excel download f summary to excel create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from foresite capital management iii llc enter your email address below and choose submit your email cancel  top buys name change blcm belcum phamcls  derm dermira inc  mnta momenta pharmaceuti  loxo loxo ongy inc  epzm epizyme inc   top sells name change ntla intellia therapeuti  akao achaogen inc  edit editas medicine inc  nstg nanostring technolo  irtc irhythm technologie   f holdings summary stock port aeri aerie pharmaceuticals  aldr alder biopharm  akao achaogen inc  aimt aimmune therapeutics inc  wve wave life sciences pte ltd  see all holdings  f activity market value  million prior market value  million new purchases stocks additional purchases stocks sold out of stocks reduced holdings in stocks top  holdings  turnover   turnover alt   time held top quarters time held top quarters time held all quarters  turnover is calculated by taking the  of new holdings initial purchases  the  of positions sold out of not just reduced divided by the total  of holdings for the quarter  alt turnover is calculated by taking either the total mv of new purchases or the mv of securities sold whichever is less divided by the total mv of the fund  f sector allocation over time fund metrics you are limited to the prior  quarters of f filings subscribe to whalewisdom to view all filing data for foresite capital management iii llc portfolio performance top  equalweighted holdings last updated on  performance for q   performance last  quarters  performance metrics stats are not available for the latest quarter backtester use whalewisdoms backtester tool to test how a hypothetical portfolio would have performed with different investment strategies research one or more filers performance and then optimize their portfolios to match your own investment goals start with one of our predefined groups or create your own view the backtesting whitepaper and the getting started page for additional help take a tour save changes to tracked backtest saving generate report at least one fund must be selected before running a backtest  ending sector allocation quarter to view current combined fdg q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings refresh advanced export download csv download excel xlsx download tsv click to see additional filters security types shares calls puts principal changes in holdings new position added to position reduced position closed out position no change ranking is in the top minimum  of shares stock ticker is etf yesno refresh edit columns shares are split adjusted × report an error your name optional your email optional error to report or any other commentsrequired cancel click here to report any possible errors with this listing f filings available   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required × csv export module this will schedule a job to export all requested f holdings data for this filer when completed an email will be sent to the email address you specify containing a link to download the zip file of the csv files you requested output type output all f holdings into a single csv file output all f holdings into separate csv files per quarter columns to include filer name stock name stock ticker quarter date type of security current shares held current market value previous shares held previous market value current  of portfolio previous  of portfolio current rank previous rank change in shares type of change sector f quarters to include       email address to send data to cancel schedule export schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free foresite capital management iii llc institutional portfolio  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  institutional portfolio foresite capital management iii llc  montgomery street san francisco california    report date  position statistics total positions  new positions  increased positions  decreased positions  positions with activity  sold out positions  total mkt value in  millions  institutional holdings information is filed by major institutions on form f with the securities and exchange commission sector weighting energy basic materials industrials consumer cyclicals consumer noncyclicals financials healthcare  technology telecommunication services utilities total positions new increased decreased activity sold out  positions as of  company class value of shares s ▼ change in value s change  shares held aerie pharmaceuticals inc com     achaogen inc com     aimmune therapeutics inc com     alder biopharmaceuticals inc com     blueprint medicines corp com     wave life sciences ltd shs  new  bellicum pharmaceuticals inc com   new  epizyme inc com     loxo oncology inc com   new  momenta pharmaceuticals inc com   new  nanostring technologies inc com     dermira inc com   new  protagonist therapeutics inc com  new  aclaris therapeutics inc com     fibrogen inc com   new  irhythm technologies inc com     ascendis pharma a s sponsored adr     intellia therapeutics inc com     natera inc com   new  immunomedics inc com   new   first previousnext last  latest news headlines cgg announces the approval of the draft safeguard plan by creditors committees in france pm et   globenewswire assembly biosciences reports inducement grants under nasdaq listing rule c pm et   globenewswire prudential bancorp inc announces third quarter fiscal  results pm et   globenewswire fncb bancorp inc announces  increase in second quarter  earnings and  increase in  pm et   globenewswire us stockssp  dented by earnings dow hits record high pm et   reuters view all latest headlines closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex